Three studies presented at the 2014 San Antonio Breast Cancer Symposium (SABCS): Cancer risk test detected 105% more mutations in cancer-causing genes than conventional BRCA testing alone; researchers at leading cancer research institutions validate use of companion diagnostic test to detect a DNA scar in tumor that is indicative of a dysfunctional DNA repair pathway; UK researchers evaluated the use of companion diagnostic assays to identify which patients would respond to carboplatin or docetaxel.
The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.
Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.
Among women with denser breasts, an additional ultrasound can detect breast cancers not discovered by mammogram.
A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.
Pictilisib and pembrolizumab may prolong survival for women with advanced breast cancer, according to data from preliminary studies.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
Although survival in male breast cancer has improved, treatment lags behind when compared to the cancer therapy women receive.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
In elderly patients with moderate- to high-risk early stage breast cancer for whom standard chemotherapy is too toxic, capecitabine did not improve outcomes when tested as monotherapy, according to recent data.
Adding tamoxifen to ovarian suppression doesn't provide a significant benefit over tamoxifen alone among premenopausal women with hormone receptor-positive early breast cancer, but the addition of ovarian suppression does benefit some of these women.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|